Fluvirin (inactivated influenza virus vaccine) / CSL Behring - LARVOL DELTA

Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy and Healthy Volunteers (clinicaltrials.gov) - P1 | N=130 | Completed | Sponsor: Roswell Park Cancer Institute | Phase classification: P4 ➔ P1

Phase classification • Acute Myelogenous Leukemia • Hematological Malignancies • Infectious Disease • Influenza • Leukemia • Myelodysplastic Syndrome • Oncology • Respiratory Diseases

Adjuvanted Influenza Vaccination in U.S. Nursing Homes (clinicaltrials.gov) - P4 | N=823 | Completed | Sponsor: Insight Therapeutics, LLC | Trial completion date: Sep 2021 ➔ Jan 2023 | Active, not recruiting ➔ Completed

Trial completion • Trial completion date • Infectious Disease • Influenza • Respiratory Diseases

Systems Analyses of the Immune Response to the Seasonal Influenza Vaccine (clinicaltrials.gov) - P2 | N=90 | Completed | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Suspended ➔ Completed | Trial completion date: Dec 2024 ➔ Jan 2023 | Trial primary completion date: Dec 2024 ➔ Jan 2023

Trial completion • Trial completion date • Trial primary completion date • Infectious Disease • Influenza • Respiratory Diseases

Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy and Healthy Volunteers (clinicaltrials.gov) - P4 | N=130 | Completed | Sponsor: Roswell Park Cancer Institute | Recruiting ➔ Completed | N=200 ➔ 130 | Trial completion date: Mar 2026 ➔ Jun 2022 | Trial primary completion date: Apr 2025 ➔ Jun 2022

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Infectious Disease • Influenza • Leukemia • Myelodysplastic Syndrome • Oncology • Respiratory Diseases

Systems Analyses of the Immune Response to the Seasonal Influenza Vaccine (clinicaltrials.gov) - P2 | N=90 | Suspended | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Trial completion date: Dec 2025 ➔ Dec 2024 | Trial primary completion date: Dec 2025 ➔ Dec 2024

Trial completion date • Trial primary completion date • Infectious Disease • Influenza • Respiratory Diseases